Tags

Type your tag names separated by a space and hit enter

Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide.
An Bras Dermatol 2019; 94(3):337-340AB

Abstract

Necrobiotic xanthogranuloma is a rare chronic condition, belonging to the group C non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly hematologic malignancies. The case reported here was only diagnosed after nine years of evolution and was associated with plasma cell dyscrasia. After treatment with cyclophosphamide, dexamethasone, and thalidomide, there was a reduction of cutaneous lesions and serum levels of monoclonal protein.

Authors+Show Affiliations

Dermatology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.Dermatology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

31365665

Citation

Mello, Renan Bernardes de, and Everton Carlos Siviero do Vale. "Necrobiotic Xanthogranuloma Associated With Smoldering Multiple Myeloma: Satisfactory Response to Cyclophosphamide, Dexamethasone, and Thalidomide." Anais Brasileiros De Dermatologia, vol. 94, no. 3, 2019, pp. 337-340.
Mello RB, Vale ECSD. Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide. An Bras Dermatol. 2019;94(3):337-340.
Mello, R. B., & Vale, E. C. S. D. (2019). Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide. Anais Brasileiros De Dermatologia, 94(3), pp. 337-340. doi:10.1590/abd1806-4841.20198500.
Mello RB, Vale ECSD. Necrobiotic Xanthogranuloma Associated With Smoldering Multiple Myeloma: Satisfactory Response to Cyclophosphamide, Dexamethasone, and Thalidomide. An Bras Dermatol. 2019 Jul 29;94(3):337-340. PubMed PMID: 31365665.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide. AU - Mello,Renan Bernardes de, AU - Vale,Everton Carlos Siviero do, Y1 - 2019/07/29/ PY - 2018/06/02/received PY - 2018/11/22/accepted PY - 2019/8/1/entrez PY - 2019/8/1/pubmed PY - 2019/9/4/medline SP - 337 EP - 340 JF - Anais brasileiros de dermatologia JO - An Bras Dermatol VL - 94 IS - 3 N2 - Necrobiotic xanthogranuloma is a rare chronic condition, belonging to the group C non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly hematologic malignancies. The case reported here was only diagnosed after nine years of evolution and was associated with plasma cell dyscrasia. After treatment with cyclophosphamide, dexamethasone, and thalidomide, there was a reduction of cutaneous lesions and serum levels of monoclonal protein. SN - 1806-4841 UR - https://www.unboundmedicine.com/medline/citation/31365665/Necrobiotic_xanthogranuloma_associated_with_smoldering_multiple_myeloma:_satisfactory_response_to_cyclophosphamide,_dexamethasone,_and_thalidomide DB - PRIME DP - Unbound Medicine ER -